Biological and mechanical therapies enabled by cardiovas

心血管支持的生物和机械疗法

• 批准号: 6822883
• 负责人: Robert J Lederman
• 金额: --
• 依托单位: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6822883
• 关键词: angiogenesis; cardiovascular disorder; cardiovascular disorder therapy; drug delivery systems; human subject; human therapy evaluation; image enhancement; magnetic resonance imaging; myocardial infarction; nonhuman therapy evaluation; stem cells; swine

During the past year we have contructed a combined x-ray and MRI interventional suite for clinical and animal research, including a custom image-reconstruction and guidance system. We have demonstrated non-toxic labeling of adult-derived stem cells and serial in-vivo surveillance of injected stem cells into the myocardium of swine using MRI. We have demonstrated direct fluoroscopic MRI targeted delivery of adult-derived stem cells into the borders of myocardial infarctions in swine. We have begun investigation of other interventional MRI applications including aortic aneurysm endograft therapy using fluoroscopic MRI. We have tested the safety of intravascular MRI in human research subjects. Studies are underway to test and develop other novel applications of fluoroscopic MRI, including cardiac valve repair and recanalization of total vascular occlusions. Finally we have begun preparation for two human research trials. One will test the safety and provisional efficacy of parenteral allogeneic adult-derived stem cell therapy for subjects recovering from a myocardial infarction. Another will test the safety and provisional efficacy of novel transcriptional regulatory factor to induce therapeutic angiogenesis, as assessed using MRI.

在过去的一年里，我们已经建立了一个结合X射线和MRI介入套件的临床和动物研究，包括一个定制的图像重建和引导系统。我们已经证明了成人来源的干细胞的无毒标记和使用MRI对注射到猪心肌中的干细胞的系列体内监测。我们已经证明了直接荧光MRI靶向输送成人来源的干细胞到猪心肌梗死的边缘。我们已经开始研究其他介入性MRI应用，包括使用X线透视MRI的主动脉瘤覆膜支架治疗。我们已经在人类研究对象中测试了血管内MRI的安全性。目前正在进行研究，以测试和开发荧光镜MRI的其他新应用，包括心脏瓣膜修复和完全血管闭塞的再通。最后，我们已经开始为两项人体研究试验做准备。其中一项将测试肠外同种异体成人源性干细胞疗法对从心肌梗死中恢复的受试者的安全性和临时疗效。另一项研究将测试新的转录调节因子诱导治疗性血管生成的安全性和临时有效性，如使用MRI评估的那样。